Are the B cells cast with the leading part in the sjogren's syndrome scenario?

Oral Diseases

Volumn 20, Issue 6, 2014, Pages 529-537

  Pers, J O ^a   Youinou, P ^a  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

Author keywords

B lymphocytes; BAFF; Flt3 ligand; Non hodgkin's lymphoma; Sj gren's syndrome

Indexed keywords

B CELL ACTIVATING FACTOR; BLOOD GROUP B ANTIBODY; CYTOKINE; RHEUMATOID FACTOR; LEUKOCYTE ANTIGEN;

B LYMPHOCYTE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; EXOCRINE GLAND; HUMAN; MEMORY CELL; NONHUMAN; ONTOGENY; PRIORITY JOURNAL; REVIEW; SJOEGREN SYNDROME; T LYMPHOCYTE; CHEMISTRY; CLASSIFICATION; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; PATHOLOGY; SALIVARY GLAND; SJOGREN'S SYNDROME;

ANTIGENS, CD; B-LYMPHOCYTE SUBSETS; CYTOKINES; HUMANS; LYMPHOCYTE COUNT; SALIVARY GLANDS; SJOGREN'S SYNDROME;

EID: 84906791357     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/odi.12153     Document Type: Review

References (100)

1. Alonso R, Buors C, Le Dantec C et al (2010). Aberrant expression of CD6 on B-cell subsets from patients with Sjogren's syndrome. J Autoimmun 35: 336-341.
2. Amft N, Bowman SJ (2001). Chemokines and cell trafficking in Sjogren's syndrome. Scand J Immunol 54: 62-69.
3. Anaya JM, McGuff HS, Banks PM, Talal N (1996). Clinicopathological factors relating malignant lymphoma with Sjogren's syndrome. Semin Arthritis Rheum 25: 337-346.
4. Anderson KC, Bates MP, Slaughenhoupt BL et al (1984). Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63: 1424-1433.
5. d'Arbonneau F, Pers JO, Devauchelle V et al (2006). BAFF-induced changes in B cell antigen receptor-containing lipid rafts in Sjogren's syndrome. Arthritis Rheum 54: 115-126.
6. Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM (2009). Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 88: 284-293.
7. Basset C, Durand V, Jamin C et al (2000). Increased N-linked glycosylation leading to oversialylation of monomeric immunoglobulin A1 from patients with Sjogren's syndrome. Scand J Immunol 51: 300-306.
8. Becker-Merok A, Nikolaisen C, Nossent HC (2006). B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 15: 570-576.
9. Bendaoud B, Pennec YL, Lelong A et al (1991). IgA-containing immune complexes in the circulation of patients with primary Sjogren's syndrome. J Autoimmun 4: 177-184.
10. Binard A, Le Pottier L, Devauchelle-Pensec V et al (2009). Is the blood B-cell subset profile diagnostic for Sjogren syndrome? Ann Rheum Dis 68: 1447-1452.
11. Bodeutsch C, de Wilde PC, Kater L et al (1993). Monotypic plasma cells in labial salivary glands of patients with Sjogren's syndrome: prognosticator for systemic lymphoproliferative disease. J Clin Pathol 46: 123-128.
12. Bohnhorst JO, Thoen JE, Natvig JB, Thompson KM (2001). Significantly depressed percentage of CD27+ (memory) B cells among peripheral blood B cells in patients with primary Sjogren's syndrome. Scand J Immunol 54: 421-427.
13. Bosello S, Youinou P, Daridon C et al (2008). Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 35: 1256-1264.
14. Boumsell L, Coppin H, Pham D et al (1980). An antigen shared by a human T cell subset and B cell chronic lymphocytic leukemic cells. Distribution on normal and malignant lymphoid cells. J Exp Med 152: 229-234.
15. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM (2010). Characteristics of the minor salivary gland infiltrates in Sjogren's syndrome. J Autoimmun 34: 400-407.
16. Cinamon G, Matloubian M, Lesneski MJ et al (2004). Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol 5: 713-720.
17. Collins CE, Gavin AL, Migone TS et al (2006). B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 8: R6.
18. Cornec D, Devauchelle-Pensec V, Tobon GJ et al (2012). B cells in Sjogren's syndrome: from pathophysiology to diagnosis and treatment. J Autoimmun 39: 161-167.
19. Cornec D, Jousse-Joulin S, Pers JO et al (2013). Contribution of salivary gland ultrasonography to the diagnosis of Sjogren's syndrome: toward new diagnostic criteria? Arthritis Rheum 65: 216-225.
20. Daridon C, Pers JO, Devauchelle V et al (2006). Identification of transitional type II B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 54: 2280-2288.
21. Daridon C, Devauchelle V, Hutin P et al (2007a). Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 56: 1134-1144.
22. Daridon C, Guerrier T, Devauchelle V et al (2007b). Polarization of B effector cells in Sjogren's syndrome. Autoimmun Rev 6: 427-431.
23. Dass S, Bowman SJ, Vital EM et al (2008). Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 67: 1541-1544.
24. Devauchelle-Pensec V, Pennec Y, Morvan J et al (2007). Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 57: 310-317.
25. Devauchelle-Pensec V, Cagnard N, Pers JO et al (2010). Gene expression profile in the salivary glands of primary Sjogren's syndrome patients before and after treatment with rituximab. Arthritis Rheum 62: 2262-2271.
26. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA (1988). Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 7: 711-717.
27. Fletcher CA, Sutherland AP, Groom JR et al (2006). Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells. Eur J Immunol 36: 2504-2514.
28. Friedman WH (1991). Factors controlling immunoglobulin production and B cell proliferation. Bull Cancer 78: 195-201.
29. Galarza C, Valencia D, Tobon GJ et al (2008). Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol 34: 124-128.
30. Gottenberg JE, Guillevin L, Lambotte O et al (2005). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64: 913-920.
31. Groom J, Kalled SL, Cutler AH et al (2002). Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 109: 59-68.
32. Guerrier T, Le Pottier L, Devauchelle V et al (2012a). Role of Toll-like receptors in primary Sjogren's syndrome with a special emphasis on B-cell maturation within exocrine tissues. J Autoimmun 39: 69-76.
33. Guerrier T, Youinou P, Pers JO, Jamin C (2012b). TLR9 drives the development of transitional B cells towards the marginal zone pathway and promotes autoimmunity. J Autoimmun 39: 173-179.
34. Halse A, Harley JB, Kroneld U, Jonsson R (1999). Ro/SS-A-reactive B lymphocytes in salivary glands and peripheral blood of patients with Sjogren's syndrome. Clin Exp Immunol 115: 203-207.
35. Hansen A, Odendahl M, Reiter K et al (2002). Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 46: 2160-2171.
36. Hansen A, Gosemann M, Pruss A et al (2004). Abnormalities in peripheral B cell memory of patients with primary Sjogren's syndrome. Arthritis Rheum 50: 1897-1908.
37. Hansen A, Reiter K, Ziprian T et al (2005). Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjogren's syndrome. Arthritis Rheum 52: 2109-2119.
38. Hansen A, Dang MA, Reiter K et al (2009). Peripheral CD27+ IgD+ IgM+ B cells in patients with primary Sjögren's syndrome and healthy donors. Ann Rheum Dis 68(Suppl 3): 204.
39. Hase H, Kanno Y, Kojima M et al (2004). BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex. Blood 103: 2257-2265.
40. Hillion S, Rochas C, Youinou P, Jamin C (2005). Expression and reexpression of recombination activating genes: relevance to the development of autoimmune states. Ann N Y Acad Sci 1050: 10-18.
41. Hillion S, Dueymes M, Youinou P, Jamin C (2007). IL-6 contributes to the expression of RAGs in human mature B cells. J Immunol 179: 6790-6798.
42. Hsu HC, Yang P, Wang J et al (2008). Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 9: 166-175.
43. Hu S, Gao K, Pollard R et al (2010). Preclinical validation of salivary biomarkers for primary Sjogren's syndrome. Arthritis Care Res (Hoboken) 62: 1633-1638.
44. Ioannidis JP, Vassiliou VA, Moutsopoulos HM (2002). Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 46: 741-747.
45. Jonsson MV, Skarstein K, Jonsson R, Brun JG (2007). Serological implications of germinal center-like structures in primary Sjogren's syndrome. J Rheumatol 34: 2044-2049.
46. Jordan R, Diss TC, Lench NJ, Isaacson PG, Speight PM (1995). Immunoglobulin gene rearrangements in lymphoplasmacytic infiltrates of labial salivary glands in Sjogren's syndrome. A possible predictor of lymphoma development. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 79: 723-729.
47. Kassan SS, Thomas TL, Moutsopoulos HM et al (1978). Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89: 888-892.
48. Le Pottier L, Bendaoud B, Renaudineau Y et al (2009a). New ELISA for B cell-activating factor. Clin Chem 55: 1843-1851.
49. Le Pottier L, Devauchelle V, Fautrel A et al (2009b). Ectopic germinal centers are rare in Sjogren's syndrome salivary glands and do not exclude autoreactive B cells. J Immunol 182: 3540-3547.
50. Lesley R, Xu Y, Kalled SL et al (2004). Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20: 441-453.
51. Mackay F, Browning JL (2002). BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2: 465-475.
52. Mackay F, Woodcock SA, Lawton P et al (1999). Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190: 1697-1710.
53. Mariette X, Roux S, Zhang J et al (2003). The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 62: 168-171.
54. Marshak-Rothstein A (2006). Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6: 823-835.
55. Matthews JB, Deacon EM, Wilson C, Potts AJ, Hamburger J (1993). Plasma cell populations in labial salivary glands from patients with and without Sjogren's syndrome. Histopathology 23: 399-407.
56. Meijer JM, Meiners PM, Vissink A et al (2010). Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62: 960-968.
57. Mitsias DI, Tzioufas AG, Veiopoulou C et al (2002). The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin Exp Immunol 128: 562-568.
58. Moutsopoulos HM (1994). Sjogren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 72: 162-165.
59. Moutsopoulos HM, Webber BL, Vlagopoulos TP, Chused TM, Decker JL (1979). Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. Am J Med 66: 733-736.
60. Odendahl M, Jacobi A, Hansen A et al (2000). Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 165: 5970-5979.
61. Pablos JL, Carreira PE, Morillas L et al (1994). Clonally expanded lymphocytes in the minor salivary glands of Sjogren's syndrome patients without lymphoproliferative disease. Arthritis Rheum 37: 1441-1444.
62. Palanichamy A, Barnard J, Zheng B et al (2009). Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol 182: 5982-5993.
63. Pascual V, Liu YJ, Magalski A et al (1994). Analysis of somatic mutation in five B cell subsets of human tonsil. J Exp Med 180: 329-339.
64. Pers JO, d'Arbonneau F, Devauchelle-Pensec V et al (2005a). Is periodontal disease mediated by salivary BAFF in Sjogren's syndrome? Arthritis Rheum 52: 2411-2414.
65. Pers JO, Daridon C, Devauchelle V et al (2005b). BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 1050: 34-39.
66. Pers JO, Devauchelle V, Daridon C et al (2007). BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum 56: 1464-1477.
67. Pijpe J, van Imhoff GW, Spijkervet FK et al (2005). Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 52: 2740-2750.
68. Ramos-Casals M, Brito-Zeron P, Yague J et al (2005). Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 44: 89-94.
69. Reif K, Ekland EH, Ohl L et al (2002). Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position. Nature 416: 94-99.
70. Roguedas AM, Pers JO, Lemasson G et al (2010). Memory B-cell aggregates in skin biopsy are diagnostic for primary Sjogren's syndrome. J Autoimmun 35: 241-247.
71. Saito T, Chiba S, Ichikawa M et al (2003). Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity 18: 675-685.
72. Salomonsson S, Jonsson MV, Skarstein K et al (2003). Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum 48: 3187-3201.
73. Schneider P, MacKay F, Steiner V et al (1999). BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189: 1747-1756.
74. Seror R, Sordet C, Guillevin L et al (2007). Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 66: 351-357.
75. Seshasayee D, Valdez P, Yan M et al (2003). Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18: 279-288.
76. Sheldon J (2004). Laboratory testing in autoimmune rheumatic diseases. Best Pract Res Clin Rheumatol 18: 249-269.
77. Shen L, Suresh L, Li H et al (2009). IL-14 alpha, the nexus for primary Sjogren's disease in mice and humans. Clin Immunol 130: 304-312.
78. Shiboski SC, Shiboski CH, Criswell L et al (2012). American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 64: 475-487.
79. Smedby KE, Hjalgrim H, Askling J et al (2006). Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 98: 51-60.
80. Speight PM, Cruchley A, Williams DM (1990). Quantification of plasma cells in labial salivary glands: increased expression of IgM in Sjogren's syndrome. J Oral Pathol Med 19: 126-130.
81. Stott DI, Hiepe F, Hummel M, Steinhauser G, Berek C (1998). Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome. J Clin Invest 102: 938-946.
82. Sutcliffe N, Inanc M, Speight P, Isenberg D (1998). Predictors of lymphoma development in primary Sjogren's syndrome. Semin Arthritis Rheum 28: 80-87.
83. Szodoray P, Alex P, Brun JG, Centola M, Jonsson R (2004). Circulating cytokines in primary Sjogren's syndrome determined by a multiplex cytokine array system. Scand J Immunol 59: 592-599.
84. Tapinos NI, Polihronis M, Tzioufas AG, Skopouli FN (1998). Immunopathology of Sjogren's syndrome. Ann Med Interne (Paris) 149: 17-24.
85. Theander E, Henriksson G, Ljungberg O et al (2006). Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65: 796-803.
86. Theander E, Vasaitis L, Baecklund E et al (2011). Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis 70: 1363-1368.
87. Thien M, Phan TG, Gardam S et al (2004). Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20: 785-798.
88. Tobon GJ, Renaudineau Y, Hillion S et al (2010). The Fms-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 62: 3447-3456.
89. Tzioufas AG, Voulgarelis M (2007). Update on Sjogren's syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Pract Res Clin Rheumatol 21: 989-1010.
90. Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM (1996). Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 39: 767-772.
91. Valentine MA, Meier KE, Rossie S, Clark EA (1989). Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem 264: 11282-11287.
92. Vitali C, Bombardieri S, Jonsson R et al (2002). Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61: 554-558.
93. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM (1999). Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum 42: 1765-1772.
94. Willenbrock K, Jungnickel B, Hansmann ML, Kuppers R (2005). Human splenic marginal zone B cells lack expression of activation-induced cytidine deaminase. Eur J Immunol 35: 3002-3007.
95. Xanthou G, Tapinos NI, Polihronis M et al (1999). CD4 cytotoxic and dendritic cells in the immunopathologic lesion of Sjogren's syndrome. Clin Exp Immunol 118: 154-163.
96. Youinou P, Jamin C (2009). The weight of interleukin-6 in B cell-related autoimmune disorders. J Autoimmun 32: 206-210.
97. Youinou P, Mackenzie L, le Masson G et al (1988). CD5-expressing B lymphocytes in the blood and salivary glands of patients with primary Sjogren's syndrome. J Autoimmun 1: 185-194.
98. Youinou P, Taher TE, Pers JO, Mageed RA, Renaudineau Y (2009). B lymphocyte cytokines and rheumatic autoimmune disease. Arthritis Rheum 60: 1873-1880.
99. Youinou P, Devauchelle-Pensec V, Pers JO (2010). Significance of B cells and B cell clonality in Sjogren's syndrome. Arthritis Rheum 62: 2605-2610.
100. Youinou P, Saraux A, Pers JO (2012). B-lymphocytes govern the pathogenesis of Sjogren's syndrome. Curr Pharm Biotechnol 13: 2071-2077.